Atrin Pharmaceuticals appoints board member
Prior to joining Egalet Dr. Dayno was vice president, global medical affairs at ViroPharma where he was also involved in early stage development for rare diseases.
Prior to ViroPharma, Dr. Dayno served as the chief medical officer at Labopharm where he first started working in the field of abuse-deterrent opioid product development.
Before Labopharm, he was vice president of global medical affairs at Cephalon.
Dr. Dayno started his career in the pharmaceutical industry in 1998 at Merck & Co. where he spent 7 years in positions of increasing responsibility in the medical and scientific affairs division.
He spent 10 years in academic and clinical medicine, involved in patient care, teaching, and clinical research.
Dr. Dayno earned his medical degree from Temple UniversitySchool of Medicine, completed his residency in Neurology at Temple University Hospital, and did a fellowship in Stroke and Cerebrovascular Disorders at Henry Ford Hospital.
Dr. Dayno is a former Chairman of the Philadelphia Stroke Council and, since 2014, has been a member of the Board of Visitors of the Lewis Katz School of Medicine at Temple University. ■
LATEST MOVES FROM Pennsylvania
- Knoll CFO Craig Spray to resign
- Highmark Health appoints Cindy Donohoe as CMO
- StoneMor Partners appoints R. Paul Grady as CEO
- DICK'S Sporting Goods appoints Lauren Hobart as president
- Bon-Ton Stores chairman Tim Grumbacher to retire
More inside POST